EUVIMEDEUVIMED entdecken
Fallbericht

Early Post‐Transplant Course and Ravulizumab in Pediatric Atypical Hemolytic Uremic Syndrome: A Case Report

Yolanda Calzada‐Baños, Marta Jiménez‐Moreno, Ana Cristina Aguilar‐Rodríguez, Bernat Gómez‐Herrera, Álvaro Madrid‐Aris, Pedro Arango‐Sancho

Pediatric Transplantation · 2026-11 · 30 (11)

DOI: 10.1111/petr.70549 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, online erschienen am 17.11.2026. Verfasst von Yolanda Calzada‐Baños und 5 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Alexion Pharmaceuticals.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atypical hemolytic uremic syndrome (aHUS) carries a high risk of recurrence after kidney transplantation, particularly in patients with complement dysregulation. Prophylactic complement inhibition has improved graft survival. However, data on ravulizumab, a long‐acting C5 inhibitor, in pediatric kidney transplantation are limited. Case Description We report a case of a 6‐year‐old girl with end‐stage renal disease secondary to aHUS, carrying a heterozygous pathogenic variant in MCP (CD46) and risk polymorphisms. Due to the aggressive disease course and donor genetics, prophylactic ravulizumab was initiated before living donor kidney transplantation. Despite a favorable initial course, the patient developed early post‐transplant complications including bleeding and suspected thrombotic microangiopathy. Ravulizumab dosing was adjusted, leading to resolution of complications. A renal biopsy 6 months post‐transplant showed no evidence of thrombotic microangiopathy. At 2 years post‐transplant, the patient maintains stable graft function and normal complement parameters.

Conclusion

This case suggests that prophylactic ravulizumab may be effective in preventing aHUS recurrence in pediatric kidney transplant recipients, even in complex genetic scenarios. Further research is needed to optimize dosing strategies and assess long‐term outcomes of ravulizumab in pediatric kidney transplantation.

Förderung

  • Alexion Pharmaceuticals

Zitieren

APA

Calzada‐Baños, Y., Jiménez‐Moreno, M., Aguilar‐Rodríguez, A. C., Gómez‐Herrera, B., Madrid‐Aris, Á., & Arango‐Sancho, P. (2026). Early Post‐Transplant Course and Ravulizumab in Pediatric Atypical Hemolytic Uremic Syndrome: A Case Report. Pediatric Transplantation, 30(11). https://doi.org/10.1111/petr.70549

Vancouver

Calzada‐Baños Y, Jiménez‐Moreno M, Aguilar‐Rodríguez AC, Gómez‐Herrera B, Madrid‐Aris Á, Arango‐Sancho P. Early Post‐Transplant Course and Ravulizumab in Pediatric Atypical Hemolytic Uremic Syndrome: A Case Report. Pediatric Transplantation. 2026;30(11). doi:10.1111/petr.70549

BibTeX
@article{CalzadaBaos2026,
  author = {Calzada‐Baños, Yolanda and Jiménez‐Moreno, Marta and Aguilar‐Rodríguez, Ana Cristina and Gómez‐Herrera, Bernat and Madrid‐Aris, Álvaro and Arango‐Sancho, Pedro},
  title = {Early Post‐Transplant Course and Ravulizumab in Pediatric Atypical Hemolytic Uremic Syndrome: A Case Report},
  journal = {Pediatric Transplantation},
  year = {2026},
  volume = {30},
  number = {11},
  doi = {10.1111/petr.70549}
}
Kostenlos starten →